位置:成果数据库 > 期刊 > 期刊详情页
细胞色素P450酶的非典型动力学研究进展
  • ISSN号:0513-4870
  • 期刊名称:药学学报
  • 时间:2012.6.6
  • 页码:725-729
  • 分类:R965.3[医药卫生—药理学;医药卫生—药学]
  • 作者机构:南昌大学临床药理研究所,南昌330006
  • 相关基金:国家自然科学基金(81260508);江西省自然科学基金(81160411)
  • 相关项目:生脉方对CYP3A4酶不同结合位点的差异影响及其机理研究
中文摘要:

目的:通过单次和多次口服1类创新药阿托伐他汀钙/阿昔莫司缓释胶囊,评价其在中国健康人体内的耐受程度和安全范围,为创新药物下一步临床试验提供安全的剂量范围和制定临床给药方案的依据。方法采用随机单中心临床研究,将38名健康受试者随机分为 A(10例)、B(10例)、C(10例)和 D(8例)4组,每组分别单次给予阿托伐他汀钙/阿昔莫司缓释胶囊1粒(260 mg,含阿托伐他汀钙10 mg+阿昔莫司250 mg)、2粒、3粒和4粒;在完成单次给药安全性良好的基础上,将相对应剂量的4组再进行多次给药的耐受性试验。观察受试者用药前后生命体征、心电图及实验室检查的变化,并记录不良事件。结果单次和多次给药耐受性试验的受试者用药前后生命体征、心电图无改变,实验室检查表明无器质性损伤;单次给药有11例、多次给药有15例受试者在口服药物15 min 后出现不同程度的斑疹或红疹,未经处理自行消退,评价为阿昔莫司的扩张血管不良反应。结论中国健康人体对阿托伐他汀钙/阿昔莫司缓释胶囊在260~1040 mg 剂量范围内单、多次给药安全性和耐受性良好,最大耐受剂量为1040 mg,推荐多次给药剂量为520~780 mg(2~3粒)。

英文摘要:

Objective To evaluate the tolerance and safety of single and multiple oral adminis-tration of atorvastatin calcium/acipimox sustained-release capsules in Chinese healthy volunteers, and to provide a safe dose range for clinical trials and a basis for development of clinical adminis-tration regimen.Methods A randomized single-center clinical trial was performed to study the tolerance of atorvastatin calcium/acipimox sustained-release capsules.Thirty-eight healthy volun-teers were randomly divided into four groups:group A (n=10),group B (n=10),group C (n=10),and group D (n=8).Each group was given single administration of 1,2,3 and 4 atorvastatin calcium/acipimox sustained-release capsules,respectively.Each capsule contained atorvastatin cal-cium 10 mg and acipimox 250 mg.On the premise of safe single administration,the tolerance of multiple administration of atorvastatin calcium/acipimox sustained-release capsules was analyzed. Vital signs,electrocardiogram and laboratory test findings were observed before and after admin-istration.In addition,adverse events were recorded.Results No changes in vital signs and elec-trocardiogram were found and no organic injuries were observed before and after single and multi-ple administration of atorvastatin calcium/acipimox sustained-release capsules.Different degrees of maculae or rash occurred 15 minutes after oral administration but spontaneously subsided with-out treatment in 11 volunteers who received single administration and 15 volunteers who received multiple administrations.The adverse side effect occurred from the blood vessel dilation caused by acipimox.Conclusion Single and multiple administration of atorvastatin calcium/acipimox sus-tained-release capsules in a range from 260 to 1 040 mg are safe and well tolerated in Chinese healthy volunteers (maximum tolerated dose 1 040 mg).The recommended doses of multiple ad-ministration of atorvastatin calcium/acipimox sustained-release capsules range from 520 to 780 mg(2-3 capsules).

同期刊论文项目
同项目期刊论文
期刊信息
  • 《药学学报》
  • 北大核心期刊(2011版)
  • 主管单位:中国科学技术协会
  • 主办单位:中国药学会 中国药学科学院药物研究所
  • 主编:王晓良
  • 地址:北京市先农坛街1号
  • 邮编:100050
  • 邮箱:yxxb@imm.ac.cn
  • 电话:010-63026192
  • 国际标准刊号:ISSN:0513-4870
  • 国内统一刊号:ISSN:11-2163/R
  • 邮发代号:2-233
  • 获奖情况:
  • 国家期刊奖,国家“双高”期刊,2002年为第2届国家期刊奖百种重点科技期刊并获第3...
  • 国内外数据库收录:
  • 俄罗斯文摘杂志,美国国际药学文摘,美国化学文摘(网络版),英国农业与生物科学研究中心文摘,波兰哥白尼索引,荷兰文摘与引文数据库,荷兰医学文摘,美国生物医学检索系统,美国生物科学数据库,日本日本科学技术振兴机构数据库,中国中国科技核心期刊,中国北大核心期刊(2004版),中国北大核心期刊(2008版),中国北大核心期刊(2011版),中国北大核心期刊(2014版),英国英国皇家化学学会文摘,瑞典开放获取期刊指南,中国北大核心期刊(2000版)
  • 被引量:37721